ConductScience.org, home

Comparison · NCT04605159-cfe24f88

RSV MAT Group - Mother vs Placebo Group - Mother: Number of Maternal Participants With at Least One MAE From Day 1 to Day 42 Post-delivery

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. RSV MAT Group - Mother vs Placebo Group - Mother: Number of Maternal Participants With at Least One MAE From Day 1 to Day 42 Post-delivery. Trial comparisons, record NCT04605159-cfe24f88. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04605159-cfe24f88

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.4830.4660.499wilson
Risk in group 20.4430.420.466wilson
Risk difference, group 1 minus group 20.03950.0110.0677newcombe hybrid score
Risk ratio, group 1 over group 21.091.021.16log
Odds ratio, group 1 over group 21.171.051.31log
Number needed to treat, for one more participant with the outcome on RSV MAT Group - Mother than on Placebo Group - Mother25.314.890.7from the risk difference interval

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1RSV MAT Group - MotherMaternal participants received a single dose of the RSV MAT vaccine administered at Day 1 in this study.1,7173,557OG000
Group 2Placebo Group - MotherMaternal participants received a single dose of placebo administered at Day 1 in this study.7851,771OG001

Outcome

Type
SECONDARY
Title
Number of Maternal Participants With at Least One MAE From Day 1 to Day 42 Post-delivery
Description
An MAE is defined as an unsolicited AE, such as a symptom or illness, which required hospitalization, or emergency room visit, or visit to/by a health care provider. At least one MAE = occurrence of at least one MAE regardless of intensity grade or relation to vaccination.
Time frame
From Day 1 to Day 42 post-delivery, an average of 2 months
Population
The analysis was performed on the Exposed Set for maternal participants, which included all maternal participants who received the study intervention.

Source ClinicalTrials.gov

Trial

Title
A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers
NCT number
NCT04605159
Phases
PHASE3
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT, Placebo
Lead sponsor
GlaxoSmithKline
Results first posted
2024-09-05

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04605159-cfe24f88